PARP1-targeted fluorescence molecular endoscopy as novel tool for early detection of esophageal dysplasia and adenocarcinoma.
Animal Models
Dysplasia
Esophageal Adenocarcinoma
Fluorescence Imaging
Fluorescence Molecular Endoscopy
PARP1
Journal
Journal of experimental & clinical cancer research : CR
ISSN: 1756-9966
Titre abrégé: J Exp Clin Cancer Res
Pays: England
ID NLM: 8308647
Informations de publication
Date de publication:
21 Feb 2024
21 Feb 2024
Historique:
received:
25
10
2023
accepted:
22
01
2024
medline:
22
2
2024
pubmed:
22
2
2024
entrez:
21
2
2024
Statut:
epublish
Résumé
Esophageal cancer is one of the 10 most common cancers worldwide and its incidence is dramatically increasing. Despite some improvements, the current surveillance protocol with white light endoscopy and random untargeted biopsies collection (Seattle protocol) fails to diagnose dysplastic and cancerous lesions in up to 50% of patients. Therefore, new endoscopic imaging technologies in combination with tumor-specific molecular probes are needed to improve early detection. Herein, we investigated the use of the fluorescent Poly (ADP-ribose) Polymerase 1 (PARP1)-inhibitor PARPi-FL for early detection of dysplastic lesions in patient-derived organoids and transgenic mouse models, which closely mimic the transformation from non-malignant Barrett's Esophagus (BE) to invasive esophageal adenocarcinoma (EAC). We determined PARP1 expression via immunohistochemistry (IHC) in human biospecimens and mouse tissues. We also assessed PARPi-FL uptake in patient- and mouse-derived organoids. Following intravenous injection of 75 nmol PARPi-FL/mouse in L2-IL1B (n = 4) and L2-IL1B/IL8Tg mice (n = 12), we conducted fluorescence molecular endoscopy (FME) and/or imaged whole excised stomachs to assess PARPi-FL accumulation in dysplastic lesions. L2-IL1B/IL8Tg mice (n = 3) and wild-type (WT) mice (n = 2) without PARPi-FL injection served as controls. The imaging results were validated by confocal microscopy and IHC of excised tissues. IHC on patient and murine tissue revealed similar patterns of increasing PARP1 expression in presence of dysplasia and cancer. In human and murine organoids, PARPi-FL localized to PARP1-expressing epithelial cell nuclei after 10 min of incubation. Injection of PARPi-FL in transgenic mouse models of BE resulted in the successful detection of lesions via FME, with a mean target-to-background ratio > 2 independently from the disease stage. The localization of PARPi-FL in the lesions was confirmed by imaging of the excised stomachs and confocal microscopy. Without PARPi-FL injection, identification of lesions via FME in transgenic mice was not possible. PARPi-FL imaging is a promising approach for clinically needed improved detection of dysplastic and malignant EAC lesions in patients with BE. Since PARPi-FL is currently evaluated in a phase 2 clinical trial for oral cancer detection after topical application, clinical translation for early detection of dysplasia and EAC in BE patients via FME screening appears feasible.
Sections du résumé
BACKGROUND
BACKGROUND
Esophageal cancer is one of the 10 most common cancers worldwide and its incidence is dramatically increasing. Despite some improvements, the current surveillance protocol with white light endoscopy and random untargeted biopsies collection (Seattle protocol) fails to diagnose dysplastic and cancerous lesions in up to 50% of patients. Therefore, new endoscopic imaging technologies in combination with tumor-specific molecular probes are needed to improve early detection. Herein, we investigated the use of the fluorescent Poly (ADP-ribose) Polymerase 1 (PARP1)-inhibitor PARPi-FL for early detection of dysplastic lesions in patient-derived organoids and transgenic mouse models, which closely mimic the transformation from non-malignant Barrett's Esophagus (BE) to invasive esophageal adenocarcinoma (EAC).
METHODS
METHODS
We determined PARP1 expression via immunohistochemistry (IHC) in human biospecimens and mouse tissues. We also assessed PARPi-FL uptake in patient- and mouse-derived organoids. Following intravenous injection of 75 nmol PARPi-FL/mouse in L2-IL1B (n = 4) and L2-IL1B/IL8Tg mice (n = 12), we conducted fluorescence molecular endoscopy (FME) and/or imaged whole excised stomachs to assess PARPi-FL accumulation in dysplastic lesions. L2-IL1B/IL8Tg mice (n = 3) and wild-type (WT) mice (n = 2) without PARPi-FL injection served as controls. The imaging results were validated by confocal microscopy and IHC of excised tissues.
RESULTS
RESULTS
IHC on patient and murine tissue revealed similar patterns of increasing PARP1 expression in presence of dysplasia and cancer. In human and murine organoids, PARPi-FL localized to PARP1-expressing epithelial cell nuclei after 10 min of incubation. Injection of PARPi-FL in transgenic mouse models of BE resulted in the successful detection of lesions via FME, with a mean target-to-background ratio > 2 independently from the disease stage. The localization of PARPi-FL in the lesions was confirmed by imaging of the excised stomachs and confocal microscopy. Without PARPi-FL injection, identification of lesions via FME in transgenic mice was not possible.
CONCLUSION
CONCLUSIONS
PARPi-FL imaging is a promising approach for clinically needed improved detection of dysplastic and malignant EAC lesions in patients with BE. Since PARPi-FL is currently evaluated in a phase 2 clinical trial for oral cancer detection after topical application, clinical translation for early detection of dysplasia and EAC in BE patients via FME screening appears feasible.
Identifiants
pubmed: 38383387
doi: 10.1186/s13046-024-02963-7
pii: 10.1186/s13046-024-02963-7
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
53Subventions
Organisme : Deutsche Forschungsgemeinschaft
ID : SFB 824 (B05: 68647618)
Informations de copyright
© 2024. The Author(s).
Références
Brown LM, Devesa SS, Chow WH. Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J Natl Cancer Inst. 2008;100(16):1184–7.
pubmed: 18695138
pmcid: 2518165
doi: 10.1093/jnci/djn211
Pohl H, Wrobel K, Bojarski C, Voderholzer W, Sonnenberg A, Rosch T, et al. Risk factors in the development of esophageal adenocarcinoma. Am J Gastroenterol. 2013;108(2):200–7.
pubmed: 23247577
doi: 10.1038/ajg.2012.387
Ryan AM, Duong M, Healy L, Ryan SA, Parekh N, Reynolds JV, et al. Obesity, metabolic syndrome and esophageal adenocarcinoma: epidemiology, etiology and new targets. Cancer Epidemiol. 2011;35(4):309–19.
pubmed: 21470937
doi: 10.1016/j.canep.2011.03.001
Levine DS. Management of dysplasia in the columnar-lined esophagus. Gastroenterol Clin North Am. 1997;26(3):613–34.
pubmed: 9309409
doi: 10.1016/S0889-8553(05)70318-6
Abrams JA, Kapel RC, Lindberg GM, Saboorian MH, Genta RM, Neugut AI, et al. Adherence to biopsy guidelines for Barrett’s esophagus surveillance in the community setting in the United States. Clin Gastroenterol Hepatol. 2009;7(7):736–42 (quiz 10).
pubmed: 19268726
pmcid: 3139243
doi: 10.1016/j.cgh.2008.12.027
Kariv R, Plesec TP, Goldblum JR, Bronner M, Oldenburgh M, Rice TW, et al. The Seattle protocol does not more reliably predict the detection of cancer at the time of esophagectomy than a less intensive surveillance protocol. Clin Gastroenterol Hepatol. 2009;7(6):653–8 (quiz 06).
pubmed: 19264576
doi: 10.1016/j.cgh.2008.11.024
Peters FP, Curvers WL, Rosmolen WD, de Vries CE, Ten Kate FJ, Krishnadath KK, et al. Surveillance history of endoscopically treated patients with early Barrett’s neoplasia: nonadherence to the Seattle biopsy protocol leads to sampling error. Dis Esophagus. 2008;21(6):475–9.
pubmed: 18430186
doi: 10.1111/j.1442-2050.2008.00813.x
Sturm MB, Wang TD. Emerging optical methods for surveillance of Barrett’s oesophagus. Gut. 2015;64(11):1816–23.
pubmed: 25975605
doi: 10.1136/gutjnl-2013-306706
Wild CP, Hardie LJ. Reflux, Barrett’s oesophagus and adenocarcinoma: burning questions. Nat Rev Cancer. 2003;3(9):676–84.
pubmed: 12951586
doi: 10.1038/nrc1166
Coda S, Thillainayagam AV. State of the art in advanced endoscopic imaging for the detection and evaluation of dysplasia and early cancer of the gastrointestinal tract. Clin Exp Gastroenterol. 2014;7:133–50.
pubmed: 24868168
pmcid: 4028486
doi: 10.2147/CEG.S58157
Vieth M, Ell C, Gossner L, May A, Stolte M. Histological analysis of endoscopic resection specimens from 326 patients with Barrett’s esophagus and early neoplasia. Endoscopy. 2004;36(09):776–81.
pubmed: 15326572
doi: 10.1055/s-2004-825802
Hvid-Jensen F, Pedersen L, Drewes AM, Sorensen HT, Funch-Jensen P. Incidence of adenocarcinoma among patients with Barrett’s esophagus. N Engl J Med. 2011;365(15):1375–83.
pubmed: 21995385
doi: 10.1056/NEJMoa1103042
Bhat S, Coleman HG, Yousef F, Johnston BT, McManus DT, Gavin AT, et al. Risk of malignant progression in Barrett’s esophagus patients: results from a large population-based study. J Natl Cancer Inst. 2011;103(13):1049–57.
pubmed: 21680910
pmcid: 3632011
doi: 10.1093/jnci/djr203
Mahmood U, Wallace MB. Molecular imaging in gastrointestinal disease. Gastroenterology. 2007;132(1):11–4.
pubmed: 17241854
doi: 10.1053/j.gastro.2006.12.013
Reid BJ, Haggitt RC, Rubin CE, Roth G, Surawicz CM, Vanbelle G, et al. Observer Variation in the Diagnosis of Dysplasia in Barretts Esophagus. Hum Pathol. 1988;19(2):166–78.
pubmed: 3343032
doi: 10.1016/S0046-8177(88)80344-7
Shiozaki H, Tahara H, Kobayashi K, Yano H, Tamura S, Imamoto H, et al. Endoscopic screening of early esophageal cancer with the Lugol dye method in patients with head and neck cancers. Cancer. 1990;66(10):2068–71.
pubmed: 1699649
doi: 10.1002/1097-0142(19901115)66:10<2068::AID-CNCR2820661005>3.0.CO;2-W
Sugimachi K, Ohno S, Matsuda H, Mori M, Kuwano H. Lugol-combined endoscopic detection of minute malignant lesions of the thoracic esophagus. Ann Surg. 1988;208(2):179–83.
pubmed: 2456747
pmcid: 1493599
doi: 10.1097/00000658-198808000-00008
Canto MI, Setrakian S, Willis J, Chak A, Petras R, Powe NR, et al. Methylene blue-directed biopsies improve detection of intestinal metaplasia and dysplasia in Barrett’s esophagus. Gastrointest Endosc. 2000;51(5):560–8.
pubmed: 10805842
doi: 10.1016/S0016-5107(00)70290-2
Ngamruengphong S, Sharma VK, Das A. Diagnostic yield of methylene blue chromoendoscopy for detecting specialized intestinal metaplasia and dysplasia in Barrett’s esophagus: a meta-analysis. Gastrointest Endosc. 2009;69(6):1021–8.
pubmed: 19215918
doi: 10.1016/j.gie.2008.06.056
Yuasa Y, Seike J, Yoshida T, Takechi H, Yamai H, Yamamoto Y, et al. Sentinel lymph node biopsy using intraoperative indocyanine green fluorescence imaging navigated with preoperative CT lymphography for superficial esophageal cancer. Ann Surg Oncol. 2012;19(2):486–93.
pubmed: 21792510
doi: 10.1245/s10434-011-1922-x
Kitagawa Y, Fujii H, Mukai M, Kubo A, Kitajima M. Sentinel lymph node mapping in esophageal and gastric cancer. Cancer Treat Res. 2005;127:123–39.
pubmed: 16209080
doi: 10.1007/0-387-23604-X_6
Lupo B, Trusolino L. Inhibition of poly(ADP-ribosyl)ation in cancer: old and new paradigms revisited. Biochem Biophys Acta. 2014;1846(1):201–15.
pubmed: 25026313
Rouleau M, Patel A, Hendzel MJ, Kaufmann SH, Poirier GG. PARP inhibition: PARP1 and beyond. Nat Rev Cancer. 2010;10(4):293–301.
pubmed: 20200537
pmcid: 2910902
doi: 10.1038/nrc2812
Aleskandarany M, Caracappa D, Nolan CC, Macmillan RD, Ellis IO, Rakha EA, et al. DNA damage response markers are differentially expressed in BRCA-mutated breast cancers. Breast Cancer Res Treat. 2015;150(1):81–90.
pubmed: 25690937
pmcid: 4344553
doi: 10.1007/s10549-015-3306-6
Bieche I, de Murcia G, Lidereau R. Poly(ADP-ribose) polymerase gene expression status and genomic instability in human breast cancer. Clin Cancer Res. 1996;2(7):1163–7.
pubmed: 9816283
Dziaman T, Ludwiczak H, Ciesla JM, Banaszkiewicz Z, Winczura A, Chmielarczyk M, et al. PARP-1 expression is increased in colon adenoma and carcinoma and correlates with OGG1. PLoS ONE. 2014;9(12):e115558.
pubmed: 25526641
pmcid: 4272268
doi: 10.1371/journal.pone.0115558
Green AR, Caracappa D, Benhasouna AA, Alshareeda A, Nolan CC, Macmillan RD, et al. Biological and clinical significance of PARP1 protein expression in breast cancer. Breast Cancer Res Treat. 2015;149(2):353–62.
pubmed: 25528020
doi: 10.1007/s10549-014-3230-1
Nosho K, Yamamoto H, Mikami M, Taniguchi H, Takahashi T, Adachi Y, et al. Overexpression of poly(ADP-ribose) polymerase-1 (PARP-1) in the early stage of colorectal carcinogenesis. Eur J Cancer. 2006;42(14):2374–81.
pubmed: 16809031
doi: 10.1016/j.ejca.2006.01.061
Ossovskaya V, Koo IC, Kaldjian EP, Alvares C, Sherman BM. Upregulation of Poly (ADP-Ribose) Polymerase-1 (PARP1) in Triple-Negative Breast Cancer and Other Primary Human Tumor Types. Genes Cancer. 2010;1(8):812–21.
pubmed: 21779467
pmcid: 3092251
doi: 10.1177/1947601910383418
Chow JP, Man WY, Mao M, Chen H, Cheung F, Nicholls J, et al. PARP1 is overexpressed in nasopharyngeal carcinoma and its inhibition enhances radiotherapy. Mol Cancer Ther. 2013;12(11):2517–28.
pubmed: 23979918
doi: 10.1158/1535-7163.MCT-13-0010
Galia A, Calogero AE, Condorelli R, Fraggetta F, La Corte A, Ridolfo F, et al. PARP-1 protein expression in glioblastoma multiforme. Eur J Histochem. 2012;56(1):e9.
pubmed: 22472897
pmcid: 3352138
doi: 10.4081/ejh.2012.e9
Staibano S, Pepe S, Lo Muzio L, Somma P, Mascolo M, Argenziano G, et al. Poly(adenosine diphosphate-ribose) polymerase 1 expression in malignant melanomas from photoexposed areas of the head and neck region. Hum Pathol. 2005;36(7):724–31.
pubmed: 16084940
doi: 10.1016/j.humpath.2005.04.017
Kossatz S, Pirovano G, Demetrio De Souza Franca P, Strome AL, Sunny SP, Zanoni DK, et al. Validation of the use of a fluorescent PARP1 inhibitor for the detection of oral, oropharyngeal and oesophageal epithelial cancers. Nat Biomed Eng. 2020;4(3):272–85.
pubmed: 32165735
pmcid: 7136849
doi: 10.1038/s41551-020-0526-9
Zhang C, Ma T, Luo T, Li A, Gao X, Wang ZG, et al. Dysregulation of PARP1 is involved in development of Barrett’s esophagus. World J Gastroenterol. 2018;24(9):982–91.
pubmed: 29531462
pmcid: 5840473
doi: 10.3748/wjg.v24.i9.982
Martin-Guerrero SM, Leon J, Quiles-Perez R, Belmonte L, Martin-Oliva D, Ruiz-Extremera A, et al. Expression and Single Nucleotide Polymorphism of Poly (ADPRibose) Polymerase-1 in Gastrointestinal Tumours: Clinical Involvement. Curr Med Chem. 2017;24(20):2156–73.
pubmed: 28302009
doi: 10.2174/0929867324666170316115039
Deeks ED. Olaparib: first global approval. Drugs. 2015;75(2):231–40.
pubmed: 25616434
doi: 10.1007/s40265-015-0345-6
Hoy SM. Talazoparib: First Global Approval. Drugs. 2018;78(18):1939–46.
pubmed: 30506138
doi: 10.1007/s40265-018-1026-z
Scott LJ. Niraparib: First Global Approval. Drugs. 2017;77(9):1029–34.
pubmed: 28474297
doi: 10.1007/s40265-017-0752-y
Syed YY. Rucaparib: First Global Approval. Drugs. 2017;77(5):585–92.
pubmed: 28247266
doi: 10.1007/s40265-017-0716-2
Reiner T, Lacy J, Keliher EJ, Yang KS, Ullal A, Kohler RH, et al. Imaging Therapeutic PARP Inhibition In Vivo through Bioorthogonally Developed Companion Imaging Agents. Neoplasia. 2012;14(3):169-IN3.
pubmed: 22496617
pmcid: 3323895
doi: 10.1593/neo.12414
Kossatz S, Brand C, Gutiontov S, Liu JT, Lee NY, Gonen M, et al. Detection and delineation of oral cancer with a PARP1 targeted optical imaging agent. Sci Rep. 2016;6:21371.
pubmed: 26900125
pmcid: 4761964
doi: 10.1038/srep21371
Demetrio de Souza Franca P, Kossatz S, Brand C, Karassawa Zanoni D, Roberts S, Guru N, et al. A phase I study of a PARP1-targeted topical fluorophore for the detection of oral cancer. Eur J Nucl Med Mol Imaging. 2021;48(11):3618–30.
pubmed: 33954826
doi: 10.1007/s00259-021-05372-6
Marcazzan S, Braz Carvalho MJ, Konrad M, Strangmann J, Tenditnaya A, Baumeister T, et al. CXCR4 peptide-based fluorescence endoscopy in a mouse model of Barrett’s esophagus. EJNMMI Res. 2022;12(1):2.
pubmed: 35006394
pmcid: 8748556
doi: 10.1186/s13550-021-00875-7
Fang HY, Stangl S, Marcazzan S, Carvalho MJB, Baumeister T, Anand A, et al. Targeted Hsp70 fluorescence molecular endoscopy detects dysplasia in Barrett’s esophagus. Eur J Nucl Med Mol Imaging. 2022;49(6):2049–63.
pubmed: 34882260
doi: 10.1007/s00259-021-05582-y
Quante M, Bhagat G, Abrams JA, Marache F, Good P, Lee MD, et al. Bile acid and inflammation activate gastric cardia stem cells in a mouse model of Barrett-like metaplasia. Cancer Cell. 2012;21(1):36–51.
pubmed: 22264787
pmcid: 3266546
doi: 10.1016/j.ccr.2011.12.004
Munch NS, Fang HY, Ingermann J, Maurer HC, Anand A, Kellner V, et al. High-Fat Diet Accelerates Carcinogenesis in a Mouse Model of Barrett’s Esophagus via Interleukin 8 and Alterations to the Gut Microbiome. Gastroenterology. 2019;157(2):492-506e2.
pubmed: 30998992
doi: 10.1053/j.gastro.2019.04.013
Kunze B, Wein F, Fang HY, Anand A, Baumeister T, Strangmann J, et al. Notch Signaling Mediates Differentiation in Barrett's Esophagus and Promotes Progression to Adenocarcinoma. Gastroenterology. 2020;159(2):575–90. https://doi.org/10.1053/j.gastro.2020.04.033 .
Pastula A, Middelhoff M, Brandtner A, Tobiasch M, Hohl B, Nuber AH, et al. Three-dimensional gastrointestinal organoid culture in combination with nerves or fibroblasts: a method to characterize the gastrointestinal stem cell niche. Stem Cells Int. 2016;2016:3710836.
pubmed: 26697073
doi: 10.1155/2016/3710836
Carney B, Kossatz S, Lok BH, Schneeberger V, Gangangari KK, Pillarsetty NVK, et al. Target engagement imaging of PARP inhibitors in small-cell lung cancer. Nat Commun. 2018;9(1):176.
pubmed: 29330466
pmcid: 5766608
doi: 10.1038/s41467-017-02096-w
Demetrio de Souza Franca P, Guru N, Roberts S, Kossatz S, Mason C, Abrahao M, et al. Fluorescence-guided resection of tumors in mouse models of oral cancer. Sci Rep. 2020;10(1):11175.
pubmed: 32636416
pmcid: 7341853
doi: 10.1038/s41598-020-67958-8
Reichert M, Takano S, Heeg S, Bakir B, Botta GP, Rustgi AK. Isolation, culture and genetic manipulation of mouse pancreatic ductal cells. Nat Protoc. 2013;8(7):1354–65.
pubmed: 23787893
pmcid: 4121532
doi: 10.1038/nprot.2013.079
Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, et al. Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012;9(7):676–82.
pubmed: 22743772
doi: 10.1038/nmeth.2019
Fang HY, Munch NS, Schottelius M, Ingermann J, Liu H, Schauer M, et al. CXCR4 Is a potential target for diagnostic PET/CT Imaging in Barrett’s dysplasia and esophageal adenocarcinoma. Clin Cancer Res. 2018;24(5):1048–61.
pubmed: 29208671
doi: 10.1158/1078-0432.CCR-17-1756
Han D, Zhang C. The oxidative damage and inflammation mechanisms in GERD-Induced Barrett’s Esophagus. Front Cell Dev Biol. 2022;10:885537.
pubmed: 35721515
pmcid: 9199966
doi: 10.3389/fcell.2022.885537
Nagengast WB, Hartmans E, Garcia-Allende PB, Peters FTM, Linssen MD, Koch M, et al. Near-infrared fluorescence molecular endoscopy detects dysplastic oesophageal lesions using topical and systemic tracer of vascular endothelial growth factor A. Gut. 2019;68(1):7–10.
pubmed: 29247063
doi: 10.1136/gutjnl-2017-314953
Gabriels RY, van Heijst LE, Hooghiemstra WTR, van der Waaij AM, Kats-Ugurlu G, Karrenbeld A, et al. Detection of Early Esophageal Neoplastic Barrett Lesions with Quantified Fluorescence Molecular Endoscopy Using Cetuximab-800CW. J Nucl Med. 2023;64(5):803–8.
pubmed: 36604181
doi: 10.2967/jnumed.122.264656
Mashimo H, Gordon SR, Singh SK. Advanced endoscopic imaging for detecting and guiding therapy of early neoplasias of the esophagus. Ann N Y Acad Sci. 2020;1482(1):61–76.
pubmed: 33184872
pmcid: 7780427
doi: 10.1111/nyas.14523
Uno K, Koike T, Hatta W, Saito M, Tanabe M, Masamune A. Development of Advanced Imaging and Molecular Imaging for Barrett's Neoplasia. Diagnostics (Basel). 2022;12(10):2437.
Vithayathil M, Modolell I, Ortiz-Fernandez-Sordo J, Oukrif D, Pappas A, Januszewicz W, et al. Image-Enhanced Endoscopy and Molecular Biomarkers Vs Seattle Protocol to Diagnose Dysplasia in Barrett’s Esophagus. Clin Gastroenterol Hepatol. 2022;20(11):2514-23e3.
pubmed: 35183768
doi: 10.1016/j.cgh.2022.01.060
Zhou J, He L, Pang Z, Appelman HD, Kuick R, Beer DG, et al. Identification and validation of FGFR2 peptide for detection of early Barrett’s neoplasia. Oncotarget. 2017;8(50):87095–106.
pubmed: 29152066
pmcid: 5675618
doi: 10.18632/oncotarget.19764
Bird-Lieberman EL, Neves AA, Lao-Sirieix P, O’Donovan M, Novelli M, Lovat LB, et al. Molecular imaging using fluorescent lectins permits rapid endoscopic identification of dysplasia in Barrett’s esophagus. Nat Med. 2012;18(2):315–21.
pubmed: 22245781
doi: 10.1038/nm.2616
Thurber GM, Reiner T, Yang KS, Kohler RH, Weissleder R. Effect of small-molecule modification on single-cell pharmacokinetics of PARP inhibitors. Mol Cancer Ther. 2014;13(4):986–95.
pubmed: 24552776
pmcid: 3981972
doi: 10.1158/1535-7163.MCT-13-0801
Sturm MB, Piraka C, Elmunzer BJ, Kwon RS, Joshi BP, Appelman HD, et al. In vivo molecular imaging of Barrett's esophagus with confocal laser endomicroscopy. Gastroenterology. 2013;145(1):56–8. https://doi.org/10.1053/j.gastro.2013.05.008 .
Joshi BP, Duan X, Kwon RS, Piraka C, Elmunzer BJ, Lu S, et al. Multimodal endoscope can quantify wide-field fluorescence detection of Barrett’s neoplasia. Endoscopy. 2016;48(2):A1–13.
pubmed: 26426999
Realdon S, Dassie E, Fassan M, Dall’Olmo L, Hatem G, Buda A, et al. In vivo molecular imaging of HER2 expression in a rat model of Barrett’s esophagus adenocarcinoma. Dis Esophagus. 2015;28(4):394–403.
pubmed: 24708360
doi: 10.1111/dote.12210
Chen J, Jiang Y, Chang TS, Rubenstein JH, Kwon RS, Wamsteker EJ, et al. Detection of Barrett’s neoplasia with a near-infrared fluorescent heterodimeric peptide. Endoscopy. 2022;54(12):1198–204.
pubmed: 35299273
pmcid: 9718637
doi: 10.1055/a-1801-2406
Bhatnagar S, Verma KD, Hu Y, Khera E, Priluck A, Smith DE, et al. Oral Administration and Detection of a Near-Infrared Molecular Imaging Agent in an Orthotopic Mouse Model for Breast Cancer Screening. Mol Pharm. 2018;15(5):1746–54.
pubmed: 29696981
pmcid: 5941251
doi: 10.1021/acs.molpharmaceut.7b00994
Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 2008;22(3):659–61.
pubmed: 17942826
doi: 10.1096/fj.07-9574LSF